Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 8, 2019
AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET
NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies ...
July 1, 2019
ASIT Biotech Continues its Transformation From Research to Late Stage Clinical Development
BRUSSELS, Belgium, July 01, 2019 (GLOBE NEWSWIRE) -- ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future ...
July 1, 2019
Genkyotex's GKT831 Prevents Multiple Complications of Portal Hypertension in Preclinical Model
ARCHAMPS, France, July 01, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX), the leading biopharmaceutical company in NOX therapies, today announced ...
July 1, 2019
Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications
Basel, Switzerland, July 01, 2019 – Basilea Pharmaceutica Ltd. (BSLN.SW) announced today that the first patient was enrolled in a newly opened cohort in the ...
July 1, 2019
Palatin Technologies Provides Mid-Calendar Year Corporate Update
CRANBURY, N.J., July 1, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of ...
July 1, 2019
aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
SAN DIEGO, July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
July 1, 2019
Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis
SOUTH SAN FRANCISCO, Calif., July 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced one oral and three poster presentations at the upcoming ...
July 1, 2019
UroGen Pharma Joins Russell 3000® Index
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it joined the broad-market ...
July 1, 2019
Spring Bank Submits IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
HOPKINTON, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
July 1, 2019
EY Names Tim Herbert, President & CEO of Inspire Medical Systems, Inc., Entrepreneur Of The Year® 2019 Award Winner in the Heartland
MINNEAPOLIS, July 01, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative ...
July 1, 2019
Checkpoint Therapeutics Added to Russell 2000® Index
NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization ...
July 1, 2019
Y-mAbs Secures Commercial Radiolabeling Capacity
NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development ...
July 1, 2019
Y-mAbs Announces Recruitment Status for Pivotal Trials
NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development ...
July 1, 2019
Krystal Biotech, Inc. Added to the Russell 2000 Index
PITTSBURGH, July 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat skin diseases, today announces that ...
July 1, 2019
Valneva Initiates Second Phase 2 Study for its Lyme Disease Vaccine Candidate VLA15
Saint-Herblain (France), July 1, 2019 – Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet ...
June 24, 2019
OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID)
NANTES, France, June 24, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) will participate in the first HealthTech Investor Daysbusiness event, hosted by ...
June 24, 2019
Final Data Analysis of Phase 2 PBC Trial Shows that Genkyotex's Anti-fibrotic Candidate GKT831 Demonstrated Statistically Significant Improvements in GGT and ALP Over Full Treatment Period
ARCHAMPS, France, June 24, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 - GKTX) announced today the final results of its Phase 2 trial of ...
June 24, 2019
BrainsWay Announces Shipment of 100th Deep Transcranial Magnetic Stimulation Helmet for the Treatment of Obsessive-Compulsive Disorder
JERUSALEM and HACKENSACK, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE:BWAY) (BrainsWay” or the “Company”), a commercial stage medical device company ...
June 24, 2019
Athenex Announces U.S. FDA Allowance of Investigational New Drug Application for PT01 (Pegtomarginase)
BUFFALO, N.Y., June 24, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
June 24, 2019
Aileron Therapeutics Strengthens Board of Directors with Appointments of William T. McKee and Josef H. von Rickenbach
WATERTOWN, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and ...
Page 8 of 158